Literature DB >> 22405100

Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides.

Elena V Rosca1, Jacob E Koskimaki, Niranjan B Pandey, Amir P Tamiz, Aleksander S Popel.   

Abstract

Structure-activity relationship (SAR) studies are essential in the generation of peptides with enhanced activity and efficacy as therapeutic agents. In this study, we report a Structure-activity relationship study for a family of mimetic peptides derived from type IV collagen with potent anti-angiogenic properties. The Structure-activity relationship study was conducted using a number of validated in vitro assays including cell proliferation, adhesion, migration, and tubule formation. We report a critical sequence (NINNV) within this peptide series, which is required for the potent anti-angiogenic activity. Detailed amino acid substitutions resulted in peptides with superior efficacy. Specifically, substitutions with isoleucine at positions 12 and 18 along with the substitution of the methionine at position 10 with the non-natural amino acid D-alanine led to an increase in potency by two orders of magnitude over the parent peptide. Several mimetic peptides in this series exhibit a significant improvement of activity over the parent peptide. This improved in vitro activity is expected to correlate with an increase in in vivo activity leading to effective peptides for anti-angiogenic therapy for different disease applications including cancer and age-related macular degeneration.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405100      PMCID: PMC3371172          DOI: 10.1111/j.1747-0285.2012.01376.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  26 in total

1.  Structure-activity relationship studies of permeability modulating peptide AT-1002.

Authors:  Min Li; Ed Oliver; Kelly M Kitchens; John Vere; Sefik S Alkan; Amir P Tamiz
Journal:  Bioorg Med Chem Lett       Date:  2008-07-15       Impact factor: 2.823

2.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

3.  Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.

Authors:  Sunny Abraham; Fang Guo; Lian-Sheng Li; Christoph Rader; Cheng Liu; Carlos F Barbas; Richard A Lerner; Subhash C Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

Review 4.  Design, synthesis, and conformation of superpotent and prolonged acting melanotropins.

Authors:  V J Hruby; S D Sharma; K Toth; J Y Jaw; F al-Obeidi; T K Sawyer; M E Hadley
Journal:  Ann N Y Acad Sci       Date:  1993-05-31       Impact factor: 5.691

5.  Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.

Authors:  Fortuna Haviv; Michael F Bradley; Douglas M Kalvin; Andrew J Schneider; Donald J Davidson; Sandra M Majest; Laura M McKay; Catherine J Haskell; Randy L Bell; Bach Nguyen; Kennan C Marsh; Bruce W Surber; John T Uchic; James Ferrero; Yi-Chun Wang; Juan Leal; Rae D Record; Jason Hodde; Stephen F Badylak; Richard R Lesniewski; Jack Henkin
Journal:  J Med Chem       Date:  2005-04-21       Impact factor: 7.446

6.  Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

Authors:  Elena V Rosca; Jacob E Koskimaki; Niranjan B Pandey; Antonio C Wolff; Aleksander S Popel
Journal:  Cancer Biol Ther       Date:  2011-11-01       Impact factor: 4.742

7.  Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Biochem Biophys Res Commun       Date:  2007-01-16       Impact factor: 3.575

Review 8.  Targeting tumors with peptides from natural sources.

Authors:  Sujit K Bhutia; Tapas K Maiti
Journal:  Trends Biotechnol       Date:  2008-03-04       Impact factor: 19.536

9.  Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.

Authors:  Laura M Kenny; R Charles Coombes; Inger Oulie; Kaiyumars B Contractor; Matthew Miller; Terence J Spinks; Brian McParland; Pamela S Cohen; Ai-Min Hui; Carlo Palmieri; Safiye Osman; Matthias Glaser; David Turton; Adil Al-Nahhas; Eric O Aboagye
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

Review 10.  Role of angiogenesis in tumor growth and metastasis.

Authors:  Judah Folkman
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

View more
  11 in total

1.  Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.

Authors:  Raquel Lima E Silva; Yogita Kanan; Adam C Mirando; Jayoung Kim; Ron B Shmueli; Valeria E Lorenc; Seth D Fortmann; Jason Sciamanna; Niranjan B Pandey; Jordan J Green; Aleksander S Popel; Peter A Campochiaro
Journal:  Sci Transl Med       Date:  2017-01-18       Impact factor: 17.956

2.  Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.

Authors:  Eric M Bressler; Jayoung Kim; Ron B Shmueli; Adam C Mirando; Hojjat Bazzazi; Esak Lee; Aleksander S Popel; Niranjan B Pandey; Jordan J Green
Journal:  J Biomed Mater Res A       Date:  2018-02-23       Impact factor: 4.396

3.  Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors.

Authors:  Jacob E Koskimaki; Esak Lee; William Chen; Corban G Rivera; Elena V Rosca; Niranjan B Pandey; Aleksander S Popel
Journal:  Angiogenesis       Date:  2012-09-29       Impact factor: 9.596

4.  Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model.

Authors:  Eugene Kim; Esak Lee; Charlesa Plummer; Stacy Gil; Aleksander S Popel; Arvind P Pathak
Journal:  Angiogenesis       Date:  2014-11-19       Impact factor: 9.596

Review 5.  Gene delivery nanoparticles to modulate angiogenesis.

Authors:  Jayoung Kim; Adam C Mirando; Aleksander S Popel; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2016-11-30       Impact factor: 15.470

6.  Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Authors:  Jayoung Kim; Raquel Lima E Silva; Ron B Shmueli; Adam C Mirando; Stephany Y Tzeng; Niranjan B Pandey; Elana Ben-Akiva; Aleksander S Popel; Peter A Campochiaro; Jordan J Green
Journal:  Acta Biomater       Date:  2019-07-30       Impact factor: 8.947

7.  A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.

Authors:  Elena V Rosca; Marie-France Penet; Noriko Mori; Jacob E Koskimaki; Esak Lee; Niranjan B Pandey; Zaver M Bhujwalla; Aleksander S Popel
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

8.  Inhibition of breast cancer growth and metastasis by a biomimetic peptide.

Authors:  Esak Lee; Seung Jae Lee; Jacob E Koskimaki; Zheyi Han; Niranjan B Pandey; Aleksander S Popel
Journal:  Sci Rep       Date:  2014-11-20       Impact factor: 4.379

9.  Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma.

Authors:  Mustafa A Barbhuiya; Adam C Mirando; Brian W Simons; Ghali Lemtiri-Chlieh; Jordan J Green; Aleksander S Popel; Niranjan B Pandey; Phuoc T Tran
Journal:  Oncotarget       Date:  2017-09-21

10.  Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.

Authors:  Adam C Mirando; Akash Patil; Christine I Rafie; Brian J Christmas; Niranjan B Pandey; Vered Stearns; Elizabeth M Jaffee; Evanthia T Roussos Torres; Aleksander S Popel
Journal:  Oncoimmunology       Date:  2020-05-14       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.